In human clinical trials, PD-1 blockage demonstrated substantial therapeutic activity to treat relapsed/refractory Hodgkin’s lymphoma as a single agent and advanced NK/TCL concurrent with chemotherapy (52, 53). Here, PDCD1 is linked to Hodgkins lymphoma.